Agios Pharmaceuticals Inc Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : And congrats on all the updates. To start off, curious what factors led you to the decision to license the PV treatment from Alnylam. And is this a model for future BD in terms of development stage and having the potential where you could add your own expertise and value? And then would you expect this asset to be broadly applicable across PV patients, or would it be more focused on a specific patient population?

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Congrats on the progress.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Maybe just a couple quick ones for me. Just following up on the in-licensed Alnylam asset. Maybe it would be helpful just to hear your thoughts and Sarah's just on the preclinical data to date. Certainly, others exploring manipulation of TMPRSS6. I'm just curious how you think this asset can potentially differentiate or sets up well when you survey the available data to date. And then secondly, great to see the dose selection for the Phase III in sickle. Just curious, just the rationale as you looked at the body of data over the last several weeks since the top line and made the step for the 100 mg. Congrats again.